Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
For endocrine therapy. Sold as Faslodex, Cligavyx, Fulvestrant. Every FDA application for this active ingredient: 3 branded and 16 generic.
As of Nov 13, 2026, FDA lists 19 applications for Fulvestrant (sold as Faslodex, Cligavyx, Fulvestrant), first approved Apr 25, 2002, with 13 new uses approved and 1 published complete response letter.
First approved: Apr 25, 2002
Applications: 19
New uses approved: 13
Complete response letters: 1
Medicare spending, 2025: $26.0M
First approved in Japan: Sep 26, 2011
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Faslodex
Part B
$18.4M
-16%
17,888
Fulvestrant
Part D
$6.4M
+33%
1,742
Fulvestrant
Part B
$1.0M
-77%
1,153
Faslodex
Part D
$252K
-23%
22
Approvals in Japan (PMDA)
First approved in Japan 113 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
FaslodexA drug with a new dosage indicated for the treatment of breast cancer. · AstraZeneca K.K. · Mar 26, 2024
FaslodexA drug with a revised indication and a new dosage for the treatment of breast cancer. · AstraZeneca K.K. · Sep 27, 2017
Faslodex, new ingredientA drug with a new active ingredient indicated for the treatment of postmenopausal breast cancer. · AstraZeneca K.K. · Sep 26, 2011
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Astrazeneca
Sandoz
Fresenius Kabi USA
Eugia Pharma
Accord Hlthcare
Apotex
Zydus Pharms
Alembic